Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors

M. Roach, David R Gandara, H. S. Yuo, P. S. Swift, S. Kroll, D. C. Shrieve, W. M. Wara, L. Margolis, T. L. Phillips

Research output: Contribution to journalArticle

221 Citations (Scopus)

Abstract

Purpose: To identify factors associated with radiation pneumonitis (RP) resulting from combined modality therapy (CMT) for lung cancer. Materials and Methods: Series published before 1994 that used CMT for the treatment of lung cancer and explicitly reported the incidence of RP are the basis for this analysis. Factors evaluated included the radiation dose per fraction (Fx), total radiation dose, fractionation scheme (split v continuous), type of chemotherapy and intended dose-intensity, overall treatment time, histology (small-cell lung cancer [SCLC] v non-small-cell lung cancer [NSCLC]), and treatment schedule (concurrent v induction, sequential, or alternating CMT). Results: Twenty-four series, including 27 treatment groups and 1,911 assessable patients, met our criteria for inclusion in this analysis. The median total dose of radiation used in the trials analyzed was 50 Gy (range, 25 to 63 Gy). The median daily Fx used was 2.0 Gy (range, 1.5 to 4.0 Gy). Nineteen series included 22 treatment groups and 1,745 patients treated with single daily fractions. Among these patients, 136 received a daily Fx greater than 2.67 Gy. Five series used twice-daily radiotherapy and included 166 patients (Fx, 1.5 to 1.7 Gy). The incidence of RP was 7.8%. In a multivariate analysis, only daily Fx, number of daily fractions, and total dose were associated with the risk of RP [P < .0001, P < .018, and P < .003, respectively). Conclusion: In this analysis, the use of Fx greater than 2.67 Gy was the most significant factor associated with an increased risk of RP. High total dose also appears to be associated with an increased risk, but twice-daily irradiation seems to reduce the risk expected if the same total daily dose is given as a single fraction. High-Fx radiotherapy should be avoided in patients who receive CMT with curative intent.

Original languageEnglish (US)
Pages (from-to)2606-2612
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number10
StatePublished - 1995

Fingerprint

Radiation Pneumonitis
Combined Modality Therapy
Lung Neoplasms
Radiation
Radiotherapy
Dose Fractionation
Therapeutics
Incidence
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Histology
Appointments and Schedules
Multivariate Analysis
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Roach, M., Gandara, D. R., Yuo, H. S., Swift, P. S., Kroll, S., Shrieve, D. C., ... Phillips, T. L. (1995). Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors. Journal of Clinical Oncology, 13(10), 2606-2612.

Radiation pneumonitis following combined modality therapy for lung cancer : Analysis of prognostic factors. / Roach, M.; Gandara, David R; Yuo, H. S.; Swift, P. S.; Kroll, S.; Shrieve, D. C.; Wara, W. M.; Margolis, L.; Phillips, T. L.

In: Journal of Clinical Oncology, Vol. 13, No. 10, 1995, p. 2606-2612.

Research output: Contribution to journalArticle

Roach, M, Gandara, DR, Yuo, HS, Swift, PS, Kroll, S, Shrieve, DC, Wara, WM, Margolis, L & Phillips, TL 1995, 'Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors', Journal of Clinical Oncology, vol. 13, no. 10, pp. 2606-2612.
Roach, M. ; Gandara, David R ; Yuo, H. S. ; Swift, P. S. ; Kroll, S. ; Shrieve, D. C. ; Wara, W. M. ; Margolis, L. ; Phillips, T. L. / Radiation pneumonitis following combined modality therapy for lung cancer : Analysis of prognostic factors. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 10. pp. 2606-2612.
@article{730dd6384a3245358e5fffc7f587e9b0,
title = "Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors",
abstract = "Purpose: To identify factors associated with radiation pneumonitis (RP) resulting from combined modality therapy (CMT) for lung cancer. Materials and Methods: Series published before 1994 that used CMT for the treatment of lung cancer and explicitly reported the incidence of RP are the basis for this analysis. Factors evaluated included the radiation dose per fraction (Fx), total radiation dose, fractionation scheme (split v continuous), type of chemotherapy and intended dose-intensity, overall treatment time, histology (small-cell lung cancer [SCLC] v non-small-cell lung cancer [NSCLC]), and treatment schedule (concurrent v induction, sequential, or alternating CMT). Results: Twenty-four series, including 27 treatment groups and 1,911 assessable patients, met our criteria for inclusion in this analysis. The median total dose of radiation used in the trials analyzed was 50 Gy (range, 25 to 63 Gy). The median daily Fx used was 2.0 Gy (range, 1.5 to 4.0 Gy). Nineteen series included 22 treatment groups and 1,745 patients treated with single daily fractions. Among these patients, 136 received a daily Fx greater than 2.67 Gy. Five series used twice-daily radiotherapy and included 166 patients (Fx, 1.5 to 1.7 Gy). The incidence of RP was 7.8{\%}. In a multivariate analysis, only daily Fx, number of daily fractions, and total dose were associated with the risk of RP [P < .0001, P < .018, and P < .003, respectively). Conclusion: In this analysis, the use of Fx greater than 2.67 Gy was the most significant factor associated with an increased risk of RP. High total dose also appears to be associated with an increased risk, but twice-daily irradiation seems to reduce the risk expected if the same total daily dose is given as a single fraction. High-Fx radiotherapy should be avoided in patients who receive CMT with curative intent.",
author = "M. Roach and Gandara, {David R} and Yuo, {H. S.} and Swift, {P. S.} and S. Kroll and Shrieve, {D. C.} and Wara, {W. M.} and L. Margolis and Phillips, {T. L.}",
year = "1995",
language = "English (US)",
volume = "13",
pages = "2606--2612",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Radiation pneumonitis following combined modality therapy for lung cancer

T2 - Analysis of prognostic factors

AU - Roach, M.

AU - Gandara, David R

AU - Yuo, H. S.

AU - Swift, P. S.

AU - Kroll, S.

AU - Shrieve, D. C.

AU - Wara, W. M.

AU - Margolis, L.

AU - Phillips, T. L.

PY - 1995

Y1 - 1995

N2 - Purpose: To identify factors associated with radiation pneumonitis (RP) resulting from combined modality therapy (CMT) for lung cancer. Materials and Methods: Series published before 1994 that used CMT for the treatment of lung cancer and explicitly reported the incidence of RP are the basis for this analysis. Factors evaluated included the radiation dose per fraction (Fx), total radiation dose, fractionation scheme (split v continuous), type of chemotherapy and intended dose-intensity, overall treatment time, histology (small-cell lung cancer [SCLC] v non-small-cell lung cancer [NSCLC]), and treatment schedule (concurrent v induction, sequential, or alternating CMT). Results: Twenty-four series, including 27 treatment groups and 1,911 assessable patients, met our criteria for inclusion in this analysis. The median total dose of radiation used in the trials analyzed was 50 Gy (range, 25 to 63 Gy). The median daily Fx used was 2.0 Gy (range, 1.5 to 4.0 Gy). Nineteen series included 22 treatment groups and 1,745 patients treated with single daily fractions. Among these patients, 136 received a daily Fx greater than 2.67 Gy. Five series used twice-daily radiotherapy and included 166 patients (Fx, 1.5 to 1.7 Gy). The incidence of RP was 7.8%. In a multivariate analysis, only daily Fx, number of daily fractions, and total dose were associated with the risk of RP [P < .0001, P < .018, and P < .003, respectively). Conclusion: In this analysis, the use of Fx greater than 2.67 Gy was the most significant factor associated with an increased risk of RP. High total dose also appears to be associated with an increased risk, but twice-daily irradiation seems to reduce the risk expected if the same total daily dose is given as a single fraction. High-Fx radiotherapy should be avoided in patients who receive CMT with curative intent.

AB - Purpose: To identify factors associated with radiation pneumonitis (RP) resulting from combined modality therapy (CMT) for lung cancer. Materials and Methods: Series published before 1994 that used CMT for the treatment of lung cancer and explicitly reported the incidence of RP are the basis for this analysis. Factors evaluated included the radiation dose per fraction (Fx), total radiation dose, fractionation scheme (split v continuous), type of chemotherapy and intended dose-intensity, overall treatment time, histology (small-cell lung cancer [SCLC] v non-small-cell lung cancer [NSCLC]), and treatment schedule (concurrent v induction, sequential, or alternating CMT). Results: Twenty-four series, including 27 treatment groups and 1,911 assessable patients, met our criteria for inclusion in this analysis. The median total dose of radiation used in the trials analyzed was 50 Gy (range, 25 to 63 Gy). The median daily Fx used was 2.0 Gy (range, 1.5 to 4.0 Gy). Nineteen series included 22 treatment groups and 1,745 patients treated with single daily fractions. Among these patients, 136 received a daily Fx greater than 2.67 Gy. Five series used twice-daily radiotherapy and included 166 patients (Fx, 1.5 to 1.7 Gy). The incidence of RP was 7.8%. In a multivariate analysis, only daily Fx, number of daily fractions, and total dose were associated with the risk of RP [P < .0001, P < .018, and P < .003, respectively). Conclusion: In this analysis, the use of Fx greater than 2.67 Gy was the most significant factor associated with an increased risk of RP. High total dose also appears to be associated with an increased risk, but twice-daily irradiation seems to reduce the risk expected if the same total daily dose is given as a single fraction. High-Fx radiotherapy should be avoided in patients who receive CMT with curative intent.

UR - http://www.scopus.com/inward/record.url?scp=0029116899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029116899&partnerID=8YFLogxK

M3 - Article

C2 - 7595714

AN - SCOPUS:0029116899

VL - 13

SP - 2606

EP - 2612

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -